Elevation raises $30M to advance nebulised LAMA for COPD
This article was originally published in Scrip
Executive Summary
Elevation Pharmaceuticals, a San Diego, California-based company focused on respiratory therapies, has closed a $30 million series B fundraising round led by new investor Novo Ventures. The funding is expected to help the three-year-old start-up advance its nebulised long-acting muscarinic antagonist (LAMA), EP-101, for the treatment of chronic obstructive pulmonary disease (COPD), and complete Phase II testing.